Details for Patent: 8,487,129
✉ Email this page to a colleague
Which drugs does patent 8,487,129 protect, and when does it expire?
Patent 8,487,129 protects PYLARIFY and PYLARIFY TRUVU and is included in two NDAs.
This patent has thirty-four patent family members in sixteen countries.
Summary for Patent: 8,487,129
| Title: | Heterodimers of glutamic acid |
| Abstract: | Compounds of Formula (Ia) wherein R is a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl, a C1-C6 substituted or unsubstituted alkyl or -NR'R', Q is C(O), O, NR', S, S(O)2, C(O)2 (CH2)p Y is C(O), O, NR', S, S(O)2, C(O)2 (CH2)p Z is H or C1-C4 alkyl, R' is H, C(O), S(O)2, C(O)2, a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl or a C1-C6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C6-C12 heteroaryl, -NR'R' or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition. Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage. |
| Inventor(s): | John W. Babich, Craig N. Zimmerman, Kevin P. Maresca |
| Assignee: | Molecular Insight Pharmaceuticals Inc |
| Application Number: | US13/294,677 |
|
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 8,487,129
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Aphelion | PYLARIFY TRUVU | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 220089-001 | Mar 6, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,487,129
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2007316391 | ⤷ Start Trial | |||
| Brazil | PI0718700 | ⤷ Start Trial | |||
| Canada | 2669127 | ⤷ Start Trial | |||
| China | 101778910 | ⤷ Start Trial | |||
| China | 103922998 | ⤷ Start Trial | |||
| Cyprus | 1116610 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
